Inactive Instrument

Context Therapeutics Inc.

Equities

US21077P1084

Biotechnology & Medical Research

Context Therapeutics shares #ASCO23 data on CLDN-6 targeted treatments and CTIM-76 update

June 13, 2023 at 01:36 pm EDT

(via NewsDirect)

Context Therapeutics CEO Marty Lehr joins Natalie Stoberman from the Proactive studios to discuss the latest data on clinical cancer target Claudin 6 (CLDN6) presented at ASCO23 and how Context’s CTIM-76 CLDN6 X CD3 bispecific antibody sets itself apart from other CLDN6-targeted clinical candidates.

Lehr says CLDN6 is differentially expressed on cancer cells with no or very low expression in normal, healthy adult tissue. CLDN6-enriched cancers include non-small cell lung (NSCLC), ovarian, testicular, and others.

CTIM-76 is currently in preclinical development and is intended to direct activated immune T cells to CLDN6-expressing cancer cells. Preclinical studies of evaluating CTIM-76 demonstrates selective immune-mediated cell death of CLDN6-positive cancer cells.

Contact Details

Proactive Investors USA

+1 347-449-0879

na-editorial@proactiveinvestors.com

Latest news about Context Therapeutics Inc.

Context Therapeutics Announces FDA Clearance of IND Application for A Phase 1 Clinical Trial of CTIM-76	May. 02	CI
Context Therapeutics Inc. announced that it expects to receive $99.992767 million in funding	Apr. 30	CI
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers	Apr. 01	CI
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Context Therapeutics Inc. Amends its Collaboration and Licensing Agreement with Integral Molecular, Inc	Mar. 06	CI
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-10	CI
Context Therapeutics Inc. Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer	23-02-06	CI
Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers	23-01-09	CI
Context Therapeutics Inc. Enrolls the First Patient in the Elona Study	23-01-04	CI
Context TherapeuticsÂ® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer	22-12-08	CI
Context Therapeutics Inc. Announces Research Collaboration and Licensing Agreement with Integral Molecular	22-11-29	CI
Context Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Certain Warrants of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2022.	22-10-18	CI
Certain Stock Options of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2022.	22-10-18	CI
Certain Common Stock of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 19-OCT-2022.	22-10-18	CI
Context Therapeutics Extends Runway into First Quarter 2024	22-09-27	CI
Context Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Context Therapeutics and the Menarini Group Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Ona-XR and Elacestrant Combination	22-08-02	CI
Context Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-11	CI
Certain Warrants of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2022.	22-04-16	CI
Certain Stock Options of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2022.	22-04-16	CI
Certain Common Stock of Context Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 17-APR-2022.	22-04-16	CI
Context Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-23	CI

Chart Context Therapeutics Inc.

Duration

Period

More charts

Company Profile

Centrexion Therapeutics Corp is a late clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to address the unmet medical need for the treatment of chronic pain. Its product candidate pipeline includes CNTX-4957, CNTX-0290, CNTX-6970, CNTX-2022 and CNTX-6016. Its product candidates are designed to treat pain conditions of multiple etiologies associated with a wide variety of common disease states. CNTX-4975 is designed to target and disrupt the signaling of pain-sensing nerve fibers. CNTX-0290 product candidate is an investigational small molecule SSTR4 agonist. CNTX-6970 is a potent and selective investigational CCR2 antagonist. CNTX-6970 is a small molecule intended to be administered orally. CNTX-2022 is a proprietary, high concentration topical gel formulation of lidocaine.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+25.69%	47.9B
LONZA GROUP AG	+46.90%	41.42B
IQVIA HOLDINGS INC.	-3.46%	40.7B
CELLTRION, INC.	-6.20%	28.92B
ICON PUBLIC LIMITED COMPANY	+9.17%	25.55B
ALNYLAM PHARMACEUTICALS, INC.	-20.42%	19.27B
BIO-TECHNE CORPORATION	+0.17%	12.15B
MEDPACE HOLDINGS, INC.	+28.07%	12.14B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.24%	11.99B

Other Biotechnology & Medical Research